Lixte Inventory vs Common Stock Analysis
LIXT Stock | USD 1.99 0.08 4.19% |
Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Inventory and its Common Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Inventory vs Common Stock
Inventory vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Inventory account and Common Stock. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Lixte Biotechnology's Inventory and Common Stock is 0.19. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Common Stock in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Inventory and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Lixte Biotechnology Holdings are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Inventory i.e., Lixte Biotechnology's Inventory and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Inventory
Common Stock
Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Lixte Biotechnology's Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 3.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 3.02 in 2024.
Lixte Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Lixte Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lixte Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
Other Current Liab | 237.9K | 10.5K | 302.9K | 394.8K | 313.9K | 171.6K | |
Total Current Liabilities | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
Total Stockholder Equity | 2.4M | 5.0M | 4.8M | 5.2M | 4.0M | 4.2M | |
Net Debt | (2.6M) | (5.1M) | (4.8M) | (5.4M) | (4.2M) | (4.0M) | |
Retained Earnings | (27.1M) | (30.4M) | (37.1M) | (43.4M) | (48.5M) | (46.1M) | |
Cash | 2.6M | 5.1M | 4.8M | 5.4M | 4.2M | 4.4M | |
Cash And Short Term Investments | 2.6M | 5.1M | 4.8M | 5.4M | 4.2M | 4.4M | |
Common Stock Shares Outstanding | 1.1M | 1.1M | 1.3M | 158.2K | 1.9M | 1.8M | |
Liabilities And Stockholders Equity | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
Other Stockholder Equity | 26.0M | 31.9M | 38.4M | 45.1M | 49.0M | 51.4M | |
Total Liab | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
Total Current Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.2M | 2.2M | |
Accounts Payable | 143.5K | 190.3K | 226.0K | 229.8K | 156.8K | 169.4K | |
Other Current Assets | 58.8K | 159.2K | 10.2K | 10.4K | 27.1K | 25.8K | |
Short Term Debt | 210.9K | 237.9K | 302.9K | 394.8K | 313.9K | 193.4K | |
Current Deferred Revenue | 94.3K | 15.8K | 77.0K | 165.0K | 157.1K | 81.5K | |
Net Tangible Assets | 625.8K | (1.1M) | 1.5M | 1.3M | 1.5M | 1.6M | |
Net Invested Capital | (1.1M) | 1.5M | 1.3M | 1.7M | 494.8K | 317K | |
Net Working Capital | 2.4M | 5.0M | 4.8M | 5.2M | 4.0M | 4.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.